Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Review Article

Intravascular adenoviral agents in cancer patients: Lessons from clinical trials

Abstract

A large number of adenoviral agents are being developed for the treatment of cancer. However, the treatment-related death of a patient with ornithine transcarbamylase deficiency following adenovirus administration by hepatic artery has led to serious concerns regarding the safety of intravascular adenovirus. Both replication-incompetent (rAd.p53, e.g., SCH58500) and replication-selective (dl1520, aka Onyx-015; CG7870) oncolytic adenoviruses, by intravascular administration, are in clinical trials. We review Phases I and I/II results from these clinical trials. dl1520 and rAd.p53 were well-tolerated following hepatic artery infusion at doses of up to 2×1012 and 2.5×1013 particles, respectively. At a dose of 7.5×1013 particles, rAd.p53 was associated with dose-limiting cardiac output suppression; dl1520 dose escalation did not proceed higher than 2×1012. Intravenous (i.v.) infusions of dl1520 and CG7870 have been well tolerated by i.v. infusion at doses of 2×1013 and 6×1012, respectively, without identification of a maximally tolerated dose to date. Mild/moderate transaminitis was demonstrated in some patients on both the hepatic arterial and i.v. trials at doses ≥1012 particles. Interleukin (IL)-6 and IL-10 were induced in a dose-dependent manner in most patients, but significant interpatient and intrapatient (on repeat doses) variabilities were demonstrated. Evidence of p53 gene expression (Ad.p53) or viral replication (dl1520) was demonstrated in the majority of patients receiving ≥1012 particles. Over 100 cancer patients have been treated with intravascular adenovirus constructs to date with an acceptable toxicity profile; further clinical trial testing appears appropriate in cancer patients.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. McCormick F . Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 2001 1: 130–141

    Article  CAS  PubMed  Google Scholar 

  2. Kozarsky KF, Wilson JM . Gene therapy: adenovirus vectors Curr Opin Genet Dev 1993 3: 499–503

    Article  CAS  PubMed  Google Scholar 

  3. Roth J, Cristiano RJ . Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997 89: 21–39

    Article  CAS  PubMed  Google Scholar 

  4. Kirn D, Martuza RL, Zwiebel J . Replication-selective virotherapy for cancer: biological principles, risk management and future directions Nat Med 2001 7: 781–787

    Article  CAS  PubMed  Google Scholar 

  5. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 1996 274: 373–376

    Article  CAS  PubMed  Google Scholar 

  6. Heise C, Hermiston T, Johnson L et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy Nat Med 2000 6: 1134–1139

    CAS  PubMed  Google Scholar 

  7. Fueyo J, Gomez-Manzano C, Alemany R et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo Oncogene 2000 19: 2–12

    Article  CAS  PubMed  Google Scholar 

  8. Hallenbeck PL, Chang YN, Hay C et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma Hum Gene Ther 1999 10: 1721–1733

    Article  CAS  PubMed  Google Scholar 

  9. Yu D, Sakamoto G, Henderson DR . Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy Cancer Res 1999 59: 1498–1504

    CAS  PubMed  Google Scholar 

  10. Yu D, Chen Y, Seng M, Dilley J, Henderson DR . The addition of adenovirus region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts Cancer Res 1999 59: 4200–4203

    CAS  PubMed  Google Scholar 

  11. Nemunaitis J, Ganly I, Khuri F et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B–55 kD gene–deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial Cancer Res 2000 60: 6359–6366

    CAS  PubMed  Google Scholar 

  12. DeWeese T, Van der Poel H, Li S et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy Cancer Res 2001 61: 7464–7472

    CAS  PubMed  Google Scholar 

  13. Vasey P, Shulman L, Gore M, Kirn D, Kaye S . Phase I trial of intraperitoneal Onyx-015 adenovirus in patients with recurrent ovarian carcinoma Proc Am Soc Clin Oncol 2000 19: 1512 abstract

    Google Scholar 

  14. Heise C, Williams A, Xue S, Propst M, Kirn D . Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy Cancer Res 1999 59: 2623–2628

    CAS  PubMed  Google Scholar 

  15. Marshall E . Clinical trials: gene therapy death prompts review of adenovirus vector Science 1999 286: 2244–2245

    Article  CAS  PubMed  Google Scholar 

  16. Beardsley T . Gene therapy setback Sci Am 2000 282: 36–37

    Article  CAS  PubMed  Google Scholar 

  17. Jenks S . Gene therapy death — everyone has to share in the guilt J Natl Cancer Inst 2000 92: 98–100

    Article  CAS  PubMed  Google Scholar 

  18. Miller H . Letter to the editor Science 2000 287: 591

    Article  CAS  PubMed  Google Scholar 

  19. Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection Virology 1987 156: 107–121

    Article  CAS  PubMed  Google Scholar 

  20. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments] Science 1996 274: 373–376

    Article  CAS  PubMed  Google Scholar 

  21. Heise C, Sampson JA, Williams A, McCormick F, Von HD, Kirn DH . ONYX-015, an E1B gene–attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments] Nat Med 1997 3: 639–645

    Article  CAS  PubMed  Google Scholar 

  22. Harada J, Berk A . p53-independent and -dependent requirements for E1B–55 kD in adenovirus type 5 replication J Virol 1999 73: 5333–5344

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H . Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells J Virol 1998 72: 9470–9478

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Goodrum FD, Ornelles DA . p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection J Virol 1998 72: 9479–9490

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Rogulski K, Freytag S, Zhang K et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy Cancer Res 2000 60: 1193–1196

    CAS  PubMed  Google Scholar 

  26. Ries SJ, Brandts CH, Chung AS et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015) Nat Med 2000 6: 1128–1133

    Article  CAS  PubMed  Google Scholar 

  27. Kirn D, Hermiston T, McCormick F . ONYX-015: clinical data are encouraging Nat Med 1998 4: 1341–1342

    Article  CAS  PubMed  Google Scholar 

  28. Kirn D, Nemunaitis J, Ganly I et al. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer Proc Am Soc Clin Oncol 1998 17: 391a

    Google Scholar 

  29. Khuri F, Nemunaitis J, Ganly I et al. A controlled trial of Onyx-015, an E1B gene–deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer Nat Med 2000 6: 879–885

    Article  CAS  PubMed  Google Scholar 

  30. Kirn DH, Khuri F, Ganly I et al. A phase II trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Proc Am Soc Clin Oncol 1999 18: 1505

    Google Scholar 

  31. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH . ONYX-015, an E1B gene–attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments] Nat Med 1997 3: 639–645

    Article  CAS  PubMed  Google Scholar 

  32. Reid A, Galanis E, Abbruzzese J, Romel L, Rubin J, Kirn D . A phase I/II trial of ONYX-015 administered by hepatic artery infusion to patients with colorectal carcinoma EORTC-NCI-AACR Meeting on Molecular Therapeutics of Cancer 1999

  33. Wills KN, Maneval DC, Menzel P et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer Hum Gene Ther 1994 5: 1079–1088

    Article  CAS  PubMed  Google Scholar 

  34. Mujoo K, Maneval D, Anderson S, Gutterman J . Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma Oncogene 1996 12: 1617–1623

    CAS  PubMed  Google Scholar 

  35. Nemunaitis J, Swisher SG, Timmons T et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer J Clin Oncol 2000 18: 609–622

    Article  CAS  PubMed  Google Scholar 

  36. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR . Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res 1997 57: 2559–2563

    CAS  PubMed  Google Scholar 

  37. Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection Virology 1987 156: 107–121

    Article  CAS  PubMed  Google Scholar 

  38. Reid T, Galanis E, Abbruzzese J et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial Gene Ther 2001 8: 1618–1626

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Reid T, Galanis E, Abbruzzese J et al. Hepatic artery infusion of Onyx-015, a replication-selective adenovirus, in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: a phase I/II clinical trial Proc Am Soc Clin Oncol 2000 19: 953 abstract

    Google Scholar 

  40. Nemunaitis J, Cunningham C, Buchanan A et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity Gene Ther 2001 8: 746–759

    Article  CAS  PubMed  Google Scholar 

  41. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA . Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver J Clin Oncol 1998 16: 1479–1489

    Article  CAS  PubMed  Google Scholar 

  42. Brusilow S, Maestri N . Urea cycle disorders: diagnosis, pathophysiology and therapy Adv Pediatr 1996 43: 127–170

    CAS  PubMed  Google Scholar 

  43. Yu D, Chen Y, Dilley J et al. Antitumor synergy of CN787, a prostate cancer–specific adenovirus, and paclitaxel and docetaxel Cancer Res 2001 61: 517–525

    CAS  PubMed  Google Scholar 

  44. Chalavi A, Todo T, Martuza R, Rabkin S . Replication-competent herpes simplex vector G207/cisplatin combination therapy for head and neck squamous cell carcinoma Neoplasia 1999 1: 162–169

    Article  Google Scholar 

  45. Norman K, Lee P . Reovirus as a novel oncolytic agent J Clin Invest 2000 105: 1035–1038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Pecora AL, Rizvi N, Cohen GI et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers J Clin Oncol 2002 20: 2251–2266

    Article  CAS  PubMed  Google Scholar 

  47. Coffey M, Strong J, Forsyth P, Lee P . Reovirus therapy of tumors with activated ras pathway Science 1998 282: 1332–1334

    Article  CAS  PubMed  Google Scholar 

  48. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL . Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nat Med 1995 1: 938–943

    Article  CAS  PubMed  Google Scholar 

  49. Roelvink P, Mi G, Einfeld D, Kovesdi I, Wickham T . Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae Science 1999 286: 1568–1571

    Article  CAS  PubMed  Google Scholar 

  50. Suzuki K, Fueyo J, Krasnykh VPR, Curiel D, Alemany R . A replicative adenovirus with enhanced infectivity shows improved oncolytic potency Clin Cancer Res 2001 7: 120–126

    CAS  PubMed  Google Scholar 

  51. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson A, Wold W . Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein J Virol 2000 74: 6147–6155

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Hermiston T . Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer J Clin Invest 2000 105: 1169–1172

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the following individuals for their contributions to these clinical trials: Jim Abbruzzese, Joe Rubin, Eva Galanis, and Alan Venook.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David Kirn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reid, T., Warren, R. & Kirn, D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 9, 979–986 (2002). https://doi.org/10.1038/sj.cgt.7700539

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700539

Keywords

This article is cited by

Search

Quick links